Clinical Scorecard: Understanding Metastasis in Gastrointestinal Cancer Through Preclinical Models

At a Glance

Key Highlights

• Mouse models have been pivotal in studying GI cancer metastasis but have limitations in translating to human physiology.
• Non-coding RNAs, such as circRERE(4–5) and miR-19b-3p, play crucial roles in metastatic progression.
• Emerging technologies like single-cell RNA sequencing enhance understanding of tumor biology and microenvironment interactions.
• Preclinical models are evolving to include non-mammalian systems and AI-driven approaches.
• The integration of patient-derived data with mechanistic studies is essential for identifying therapeutic vulnerabilities.

Guideline-Based Recommendations

Diagnosis

• Utilize biomarkers such as circulating miR-19b-3p for assessing disease progression.

Management

• Consider targeting non-coding RNA pathways for therapeutic intervention.

Monitoring & Follow-up

• Monitor levels of circRERE(4–5) and miR-19b-3p in patient plasma for prognostic insights.

Risks

• 80% of novel therapies that showed promise in mouse studies fail in human trials.

Patient & Prescribing Data

Patients with advanced gastrointestinal cancers.

Antisense oligonucleotide-mediated silencing of circRERE(4–5) shows potential in reducing tumor growth and metastasis.

Clinical Best Practices

• Incorporate findings from preclinical models into clinical trial designs.
• Focus on the tumor microenvironment in therapeutic strategies.
• Utilize advanced imaging and genome editing technologies in research.

Related Resources & Content

• Frontiers in Oncology Research Topic